| Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19 L Naymagon, N Zubizarreta, J Feld, M van Gerwen, M Alsen, S Thibaud, ... Thrombosis research 196, 99-105, 2020 | 174 | 2020 |
| Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study D Tremblay, M Van Gerwen, M Alsen, S Thibaud, A Kessler, S Venugopal, ... Blood, The Journal of the American Society of Hematology 136 (1), 144-147, 2020 | 159 | 2020 |
| Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation A Sacher, P LoRusso, MR Patel, WH Miller Jr, E Garralda, MD Forster, ... New England Journal of Medicine 389 (8), 710-721, 2023 | 142 | 2023 |
| Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study AL Schmidt, Z Bakouny, S Bhalla, JA Steinharter, DA Tremblay, MM Awad, ... Cancer cell 38 (6), 769-770, 2020 | 70 | 2020 |
| Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 66 | 2020 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 61 | 2021 |
| Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 61 | 2020 |
| Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 58 | 2021 |
| Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial MD Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, KG Chan, ... Nature medicine 29 (11), 2825-2834, 2023 | 55 | 2023 |
| HBV/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV R Rajbhandari, T Jun, H Khalili, RT Chung, AN Ananthakrishnan Journal of viral hepatitis 23 (10), 820-829, 2016 | 51 | 2016 |
| Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial J Desai, G Alonso, SH Kim, A Cervantes, T Karasic, L Medina, ... Nature Medicine 30 (1), 271-278, 2024 | 49 | 2024 |
| Convalescent plasma for the treatment of severe COVID‐19 infection in cancer patients D Tremblay, C Seah, T Schneider, S Bhalla, J Feld, L Naymagon, B Wang, ... Cancer medicine 9 (22), 8571-8578, 2020 | 46 | 2020 |
| Analysis of sex-specific risk factors and clinical outcomes in COVID-19 T Jun, S Nirenberg, T Weinberger, N Sharma, E Pujadas, ... Communications Medicine 1 (1), 3, 2021 | 45 | 2021 |
| Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma P Fessas, M Naeem, M Pinter, TU Marron, D Szafron, L Balcar, A Saeed, ... Liver Cancer 10 (6), 583-592, 2021 | 44 | 2021 |
| Gene networks that compensate for crosstalk with crosstalk IE Müller, JR Rubens, T Jun, D Graham, R Xavier, TK Lu Nature Communications 10 (1), 4028, 2019 | 42 | 2019 |
| A review of longitudinal clinical programs in US medical schools G Gheihman, T Jun, GJ Young, D Liebman, K Sharma, E Brandes, B Ogur, ... Medical Education Online 23 (1), 1444900, 2018 | 40 | 2018 |
| Genomic and molecular features distinguish young adult cancer from later-onset cancer W Lee, Z Wang, M Saffern, T Jun, K Huang Cell reports 37 (7), 2021 | 39 | 2021 |
| Mac‐2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection T Jun, YC Hsu, S Ogawa, YT Huang, ML Yeh, CH Tseng, CF Huang, ... Hepatology communications 3 (4), 493-503, 2019 | 36 | 2019 |
| More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma TW Jun, ML Yeh, JD Yang, VL Chen, P Nguyen, NH Giama, CF Huang, ... Liver International 38 (5), 895-902, 2018 | 33 | 2018 |
| Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B YC Hsu, T Jun, YT Huang, ML Yeh, CL Lee, S Ogawa, SH Cho, JT Lin, ... Alimentary pharmacology & therapeutics 48 (10), 1128-1137, 2018 | 32 | 2018 |